Clinical Trial Update: Expanding Phase III Study of Tyroserleutide for Injection [Phase 3]

View source ↗

Summary

A Phase III study of Tyroserleutide for injection is being expanded to enroll more patients in hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Tyroserleutide

Snippet

Sponsor: Shenzhen Kangzhe Pharmaceutical Co., Ltd. | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: UNKNOWN